Memantine drug interactions

From Pubdrug

Contents 1 Drug-drug interactions 2 Drug-food/drug-herb interactions 3 References

This page has been completed and reviewed for accuracy. You are reading a certified PubDrug document. This document is complete and accurate to the best of the knowledge of the author and reviewer. This document cannot be edited without being unlocked by a PubDrug admin. Edits or updates may be recommended under the Discussion tab. Authored by: Km39 05:37, 20 March 2007 (PDT) Certified by: Rlweber 14:50, 24 April 2007 (PDT)

Back to monograph page

Drug-drug interactions

Severity level	Drug and description of interaction
4	dofetilide: May compete for renal tubular secretion. This competition may result in increased concentrations, and therefore increased side effects, of either drug. For dofetilide, this could mean an increase in potentially fatal arrhythmias.[1]
3	metformin: May increase the risk of lactic acidosis.[2] procainamide, quinidine: May compete for renal tubular secretion. This competition may result in increased concentrations, and therefore increased side effects, of either drug.[3][4]
2	acetazolamide, methazolamide: These drugs increase the pH of the urine thus decreasing the elimination of memantine, which can lead to increased side effects of memantine.[5] adefovir, cimetidine, digoxin, entecavir, lamivudine, midodrine, morphine, quinine, trimethoprim, trospium, vancomycin: May compete for renal tubular secretion. This competition may result in increased concentrations, and therefore increased side effects, of either drug.[6][7][8][9][10][11][12][13][14][15] amantadine, dextromethorphan, ketamine: May increase the risk for CNS adverse effects. These drugs and memantine are all NMDA antagonists.[5] antimuscarinics: Antimuscarinics side effects may be increased with the coadministration of memantine. Adverse effects to watch for include urinary retention, dry mouth and blurred vision.[16] bromocriptine, levodopa, pergolide, pramipexole, ropinirole: The effects of dopamine agonists will be increased when coadministered with memantine.[5]
1	amiloride, nicotine, ranitidine: May compete for renal tubular secretion. This competition may result in increased concentrations, and therefore increased side effects, of either drug.[5][17][18] hydrochlorothiazide: The AUC of hydrochlorothiazide was decreased by 20%.[5]

Drug-food/drug-herb interactions

Severity level	Drug and description of interaction
4	None known
3	None known
2	None known
1	None known

References

1. ↑ Tikosyn™ (dofetilide)package insert. New York, NY: Pfizer Labs; 1999 Dec.
2. ↑ Glucophage®/Glucophage® XR (metformin) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2003 Apr.
3. ↑ Procanbid® (procainamide) package insert. Bristol, TN: Monarch Pharmaceuticals; 2002 Jan.
4. ↑ Quinidex Extentabs® (quinidine sulfate extended-release tablets) package insert. Richmond, VA: A.H. Robbins Company; 2000 Sept.
5. ↑ ^{5.0 5.1 5.2 5.3 5.4}
6. ↑ Hepsera® (adefovir dipivoxil) package insert. Foster City, CA: Gilead Sciences, Inc.; 2006 Sep.
7. ↑ Somogyi A, Muirhead M. Pharmacokinetic interactions of cimetidine, 1987. Clin Pharmacokinet 1987;12:321—66.
8. ↑ Lanoxin® (digoxin) package insert. Research Triangle Park, NC: Glaxo Smith Kline; 2001 Aug.
9. ↑ Baraclude™ (entecavir) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2005 Mar.
10. ↑ Moore K, Raasch R, Yuen G et al. Pharmacokinetics (PK) of lamivudine (3TC) administered alone and with oral trimethoprim (TMP) plus sulfamethoxazole (SMX) in patients with human immunodeficiency virus (HIV) infection (abstract). Clin Pharmacol Ther 1995;57:143.
11. ↑ ProAmatine® (midodrine) package insert. Austria, GmbH: Nycomed; 2003 Oct.
12. ↑ Bonate PL, Reith K, Weir S. Drug interactions at the renal level: Implications for drug development. Clin Pharmacokinet 1998;34:375—404.
13. ↑ Bendayan R. Renal drug transport: A review. Pharmacotherapy 1996;16:971—85.
14. ↑ Proloprim® (trimethoprim) package insert. Bristol, TN: Monarch Pharmaceuticals, Inc.; 2000 Jan.
15. ↑ Sanctura™ (trospium) package insert. Lexington, MA: Indevus Pharmaceuticals, Inc.; 2004 May.
16. ↑ Food and Drug Administration (FDA). NDA Safety Review: NDA 21-487, Memantine, Forest Laboratories, Inc.;August 20, 2003. Retrieved July 12, 2004. Available on the World Wide Web at http://www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA-Safety%20Review.pdf.
17. ↑ Bendayan R. Renal drug transport: A review. Pharmacotherapy 1996;16:971—85.
18. ↑ Zantac® (ranitidine) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006 Jul.